Acepodia Raises $47 Million Funding to Nurture its Next-Gen, oNK Cell Therapy Assets
What if we could enhance the potential of Natural Killer (NK) cell therapies which offers key advantages over CAR T-cell therapies? Acepodia, a privately held US-Taiwan biotech, develops next-generation, off-the-shelf …
Read More